--- title: Investigation of Bempedoic Acid DDI Potential In A SCHH Model Registration --- [![BioIVT_4C_Logo w Tagline-01-1](https://info.bioivt.com/hs-fs/hubfs/BioIVT_4C_Logo%20w%20Tagline-01-1.png?width=250&name=BioIVT_4C_Logo%20w%20Tagline-01-1.png)](https://bioivt.com/)   LIVE WEBINAR # Investigation of Bempedoic Acid DDI Potential In A SCHH Model November 11, 2021 11 AM ET, 8AM PT, 4PM GMT [Register Now](https://info.bioivt.com/ddi-reg#register-form) ## Event Overview In this webinar, we will discuss how a sandwich-cultured human hepatocyte (SCHH) model was used to investigate the DDI potential of bempedoic acid, a drug indicated for hypercholesterolemia. Also known as Nexletol®, bempedoic acid was approved by the FDA in 2020. It is a first-in-class, adenosine triphosphate-citrate lyase (ACL) inhibitor for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Dr. Maurice Emery, Executive Director, Esperion Therapeutics, will review the results of a study to assess the effect of bempedoic acid on the hepatic disposition of warfarin and naproxen, two well-characterized, OAT2 substrates. He will also discuss the potential clinical implications of this work. Dr. Kenneth R Brouwer, VP ADME-Tox, BioIVT, will discuss the SCHH model, a “whole-cell” system that can improve IVIVC investigation of transporter-mediated hepatic disposition. Attend our webinar for an engaging discussion of the following topics: • Bempedoic acid pharmacokinetic interactions with warfarin and naproxen • The benefits of a SCHH model for DDI disposition studies • OAT2-mediated hepatic uptake in pharmacokinetics ## Speakers ![Browuer_HS](https://info.bioivt.com/hs-fs/hubfs/Headshots_WBR%20(93).png?width=300&height=300&name=Headshots_WBR%20(93).png) Kenneth R. Brouwer, PhD, RPH Vice President, ADME-Tox Research, BioIVT | **Kenneth R. Brouwer, PhD, RPH, is Vice President**, ADME-Tox Research at BioIVT. A pharmacologist by training, Dr. Brouwer has led *in vitro* ADME programs at GSK and at PPD. He later led development of B-CLEAR technology, a method to quantitate hepatobiliary excretion. He was a founder of Qualyst Transporter Solutions, where he expanded applications of B-CLEAR technology and developed assays that integrate uptake, efflux, and regulatory function of cells. In 2017, BioIVT acquired Qualyst, and Dr. Brouwer now helps biopharmaceutical clients design and implement *in vitro* ADME research programs to achieve their drug R&D and regulatory submission objectives. | | --- |     ![Headshots_WBR (92)](https://info.bioivt.com/hs-fs/hubfs/Headshots_WBR%20(92).png?width=300&height=300&name=Headshots_WBR%20(92).png) Maurice G. Emery, PharmD, PhD Executive Director, Esperion Therapeutics   | **Maurice G. Emery, PharmD, PhD**, has over 10 years’ experience in academia and 20 years' experience in drug discovery and development. His work in drug development spans oncology, inflammation, metabolic and cardiovascular therapeutics, and he has helped bring several novel therapies to approval. Dr. Emery is on the Board of Directors of the American Society of Clinical Pharmacology and Therapeutics. He has authored four book chapters and over 40 peer-reviewed publications. He and his wife live on the slopes of Haleakala in Upcountry Maui, Hawai’i. They have four daughters and three Nigerian dwarf dairy goats. | | --- |   ## Agenda 11:00 - 11:05 Introduction 11:05 - 11:45 Presentation 11:45 - 12:00 Live Q&A Session ## Save Your Seat ### Sign up for our newsletter We’ll send you periodic updates about new products and services BioIVT will use the information you have provided above to service your request/inquiry. In addition, our sales and marketing team would like to use your contact information to connect with you about specific BioIVT products and services that we think might be of interest to you. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our [Privacy Policy](https://www.bioivt.com/privacy-policy/). ### Questions? You can reach us by phone, email or [click here to contact us.](https://www.bioivt.com/about/contact-us/) ### North America & Asia Pacific [516-483-1196](tel:516-483-1196) [customerservice@bioivt.com](mailto:customerservice@bioivt.com) ### Europe, Middle East & Africa [+ 44 1444 707333](tel:+%2044%201444%20707333) [cseurope@bioivt.com](mailto:cseurope@bioivt.com) ©2020 BioIVT. BIOIVT and ELEVATING SCIENCE are a registered trademarks of BioIVT. - [Trademarks](https://www.bioivt.com/trademarks) - [Privacy Policy](https://www.bioivt.com/privacy-policy) - [Terms and Conditions](https://www.bioivt.com/terms-and-conditions)